Enveric Biosciences (NASDAQ:ENVB – Get Free Report) is expected to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($6.00) per share for the quarter.
Enveric Biosciences Price Performance
Shares of Enveric Biosciences stock opened at $1.73 on Monday. Enveric Biosciences has a 1 year low of $1.13 and a 1 year high of $28.05. The business has a 50-day moving average of $3.13 and a two-hundred day moving average of $5.23. The company has a market capitalization of $1.17 million, a P/E ratio of -0.05 and a beta of 0.47.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Enveric Biosciences in a report on Thursday, March 6th.
Enveric Biosciences Company Profile
Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.
Featured Stories
- Five stocks we like better than Enveric Biosciences
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- How to Build the Ultimate Everything ETF Portfolio
- What is the MACD Indicator and How to Use it in Your Trading
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- Health Care Stocks Explained: Why You Might Want to Invest
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Enveric Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enveric Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
